On June 28 and 29, academic thought leaders and high-ranking officers
from pharma, biotech and information technology companies will gather in
Paris at the 4th
WIN Symposium to present and discuss breakthroughs that will bring
personalized cancer medicine to the next phase. The Symposium will
address new ways to advance individualized cancer therapy by applying
new technologies, including targeted therapeutics and diagnostic
biomarkers, and by designing and conducting innovative clinical trials
in oncology. The program will include the first-ever disclosure of new
technologies that are able to predict the efficacy of therapeutics for
the treatment of cancer patients on an individual basis.
Both sides - academia and industry - will equally contribute to the
presentations and discussions. Experts participating from the academic
side include: James Doroshow (NCI), Ronald DePinho (USA), John
Mendelsohn (USA); Alexander Eggermont (France); William
Dalton (USA), Richard L. Schilsky (USA), Leroy Hood
(Canada), and others. Industry will be represented by among others Brett
Davis (Oracle Corporation), Richard Gaynor (Eli Lilly and
Company), Steven Averbuch (Bristol-Myers Squibb), Nick Botwood
(AstraZeneca), Paolo Paoletti (GlaxoSmithKline), and Christopher
Viehbacher (Sanofi).
The program has received endorsements by ASCO, ESMO, UICC and INCa.
It has been recognized as one of educational value for medical
specialists, which is reflected by the awarding of 12 European CME
credits and 17 ESMO MORA credits.
The 4th WIN Symposium is the next annual of the WIN
Consortium (www.winconsortium.org),
a joint initiative of Cancer Institute Gustave Roussy, France, and The
University of Texas - MD Anderson Cancer Center, USA, which brings
together 22 cancer centers from around the world and technology
partners, including Agilent Technologies, GE Healthcare, Life
Technologies, and Foundation Medicine.
Advance registration for the symposium at reduced rates remains open
until June 24 via the WIN
Consortium website. On-site registration in Paris will be open as of
June 27.